Skip to main content
SpringerLink
Log in

Biomarkers of Gynecological Cancers

  • Chapter
  • First Online:
Biomarkers in Cancer Therapy

  • 687 Accesses

Abstract

Tumor markers are molecules or substances produced by malignant tumors or the surrounding tissues that enter the circulation in detectable amounts. The majority of biomarkers are tumor-associated rather than tumor-specific and show elevated levels in multiple cancers. Tumor markers thus can be helpful for differential diagnosis but are not themselves diagnostic. In the field of gynecologic malignancies, biomarkers of ovarian cancer have been eagerly investigated owing to the difficulty in screening. Despite large efforts to develop novel biomarkers, cancer antigen 125 (CA125) has been the only biomarker clinically used, and no other marker has been able to outperform CA125. Noncoding RNAs, metabolites, and circulating tumor DNAs have recently emerged as cancer biomarkers and are being applied to clinical practice. Genomic biomarkers with predictive values are now used to select therapeutic drugs, especially molecular-targeted drugs. In this chapter, we describe ovarian cancer biomarkers in detail. In addition, biomarkers of uterine cancer and cervical cancer are summarized.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from http://globocan.iarc.fr/Pages/fact_sheets_population.aspx (2012).

  2. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol. 2009;40(9):1213–23.

    Article  CAS  PubMed  Google Scholar 

  3. Yang WL, Lu Z, Bast RC Jr. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn. 2017;17(6):577–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68(5):1331–7.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kabawat SE, Bast RC Jr, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol. 1983;2(3):275–85.

    Article  CAS  PubMed  Google Scholar 

  6. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309(15):883–7.

    Article  PubMed  Google Scholar 

  7. Bon GG, Kenemans P, Verstraeten R, van Kamp GJ, Hilgers J. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. Am J Obstet Gynecol. 1996;174(1 Pt 1):107–14.

    Article  CAS  PubMed  Google Scholar 

  8. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4(1):1–12.

    Article  CAS  PubMed  Google Scholar 

  9. Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol. 2012;206(4):351.e1–8.

    Article  CAS  Google Scholar 

  10. Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem. 2011;57(11):1534–44.

    Article  CAS  PubMed  Google Scholar 

  11. Rustin GJ, van der Burg ME, Berek JS. Advanced ovarian cancer. Tumour markers. Ann Oncol. 1993;4(Suppl 4):71–7.

    Article  PubMed  Google Scholar 

  12. Berek JS, Bast RC Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer. 1995;76(10 Suppl):2092–6.

    Article  CAS  PubMed  Google Scholar 

  13. Skates SJ, Xu FJ, Yu YH, Sjovall K, Einhorn N, Chang Y, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995;76(10 Suppl):2004–10.

    Article  CAS  PubMed  Google Scholar 

  14. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet. 1999;353(9160):1207–10.

    Article  CAS  PubMed  Google Scholar 

  15. Genetic risk and screening techniques for epithelial ovarian cancer. ACOG Committee Opinion: Committee on Gynecologic Practice. Number 117—December 1992. Int J Gynaecol Obstet. 1993;41(3):321–3.

    Google Scholar 

  16. Woodward ER, Sleightholme HV, Considine AM, Williamson S, McHugo JM, Cruger DG. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG. 2007;114(12):1500–9.

    Article  CAS  PubMed  Google Scholar 

  17. Hermsen BB, Olivier RI, Verheijen RH, van Beurden M, de Hullu JA, Massuger LF, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer. 2007;96(9):1335–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Bonfrer JM, Korse CM, Verstraeten RA, van Kamp GJ, Hart GA, Kenemans P. Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of a reference value. Clin Chem. 1997;43(3):491–7.

    CAS  PubMed  Google Scholar 

  19. Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 1993;306(6884):1030–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol. 2005;23(31):7919–26.

    Article  PubMed  Google Scholar 

  21. Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013;119(19):3454–61.

    Article  PubMed  Google Scholar 

  22. Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, et al. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol. 2015;33(18):2062–71.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Kobayashi H, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer. 2008;18(3):414–20.

    Article  CAS  PubMed  Google Scholar 

  24. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10(4):327–40.

    Article  PubMed  Google Scholar 

  25. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945–56.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295–303.

    Article  CAS  PubMed  Google Scholar 

  27. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009;113(4):775–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402–16.

    Article  CAS  PubMed  Google Scholar 

  29. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81(2):214–8.

    Article  CAS  PubMed  Google Scholar 

  30. Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, Hayward J, et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol. 2015;33(26):2901–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP, et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J Natl Cancer Inst. 2015;107(11).

    Google Scholar 

  32. Olivier RI, Lubsen-Brandsma MA, Verhoef S, van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol. 2006;100(1):20–6.

    Article  CAS  PubMed  Google Scholar 

  33. NCCN Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: breast and ovarian. Version 2. 2017.

    Google Scholar 

  34. Rosenthal AN, Fraser LSM, Philpott S, Manchanda R, Burnell M, Badman P, et al. Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom Familial Ovarian Cancer Screening Study. J Clin Oncol. 2017;35(13):1411–20.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Skates SJ, Greene MH, Buys SS, Mai PL, Brown P, Piedmonte M, et al. early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk – combined results from two screening trials. Clin Cancer Res. 2017;23(14):3628–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Jeyarajah AR, Ind TE, Skates S, Oram DH, Jacobs IJ. Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. Cancer. 1999;85(9):2068–72.

    Article  CAS  PubMed  Google Scholar 

  37. Jeyarajah AR, Ind TE, MacDonald N, Skates S, Oram DH, Jacobs IJ. Increased mortality in postmenopausal women with serum CA125 elevation. Gynecol Oncol. 1999;73(2):242–6.

    Article  CAS  PubMed  Google Scholar 

  38. Sjovall K, Nilsson B, Einhorn N. The significance of serum CA 125 elevation in malignant and nonmalignant diseases. Gynecol Oncol. 2002;85(1):175–8.

    Article  PubMed  Google Scholar 

  39. Hogdall CK, Norgaard-Pedersen B, Mogensen O. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer. Anticancer Res. 2002;22(3):1765–8.

    CAS  PubMed  Google Scholar 

  40. Petri AL, Hogdall E, Christensen IJ, Kjaer SK, Blaakaer J, Hogdall CK. Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer. APMIS. 2006;114(5):359–63.

    Article  CAS  PubMed  Google Scholar 

  41. Paramasivam S, Tripcony L, Crandon A, Quinn M, Hammond I, Marsden D, et al. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. J Clin Oncol. 2005;23(25):5938–42.

    Article  CAS  PubMed  Google Scholar 

  42. Makar AP, Kristensen GB, Kaern J, Bormer OP, Abeler VM, Trope CG. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol. 1992;79(6):1002–10.

    CAS  PubMed  Google Scholar 

  43. Markman M, Liu PY, Rothenberg ML, Monk BJ, Brady M, Alberts DS. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol. 2006;24(9):1454–8.

    Article  CAS  PubMed  Google Scholar 

  44. Makar AP, Kristensen GB, Bormer OP, Trope CG. Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer? Gynecol Oncol. 1993;49(1):3–7.

    Article  CAS  PubMed  Google Scholar 

  45. Gallion HH, Hunter JE, van Nagell JR, Averette HE, Cain JM, Copeland LJ, et al. The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer. Gynecol Oncol. 1992;46(1):29–32.

    Article  CAS  PubMed  Google Scholar 

  46. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419–23.

    Article  PubMed  Google Scholar 

  47. Fehm T, Heller F, Kramer S, Jager W, Gebauer G. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Res. 2005;25(3a):1551–4.

    PubMed  Google Scholar 

  48. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155–63.

    Article  PubMed  Google Scholar 

  49. Soletormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European group on tumor markers. Int J Gynecol Cancer. 2016;26(1):43–51.

    Article  PubMed  Google Scholar 

  50. Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene. 1999;238(2):375–85.

    Article  CAS  PubMed  Google Scholar 

  51. Kirchhoff C, Habben I, Ivell R, Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991;45(2):350–7.

    Article  CAS  PubMed  Google Scholar 

  52. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65(6):2162–9.

    Article  CAS  PubMed  Google Scholar 

  53. Moore RG, Plante B, Hartnett E, Mitchel J, Raker CA, Vitek W, et al. Assessment of serum HE4 levels throughout the normal menstrual cycle. Am J Obstet Gynecol. 2017;217(1):53.e1–9.

    Article  CAS  Google Scholar 

  54. Urban N, Thorpe JD, Bergan LA, Forrest RM, Kampani AV, Scholler N, et al. Potential role of HE4 in multimodal screening for epithelial ovarian cancer. J Natl Cancer Inst. 2011;103(21):1630–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila). 2011;4(3):375–83.

    Article  Google Scholar 

  56. Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC Jr, Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol. 2012;206(4):349.e1–7.

    Article  CAS  Google Scholar 

  57. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112(1):40–6.

    Article  CAS  PubMed  Google Scholar 

  58. Terry KL, Schock H, Fortner RT, Husing A, Fichorova RN, Yamamoto HS, et al. A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort. Clin Cancer Res. 2016;22(18):4664–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Fortner RT, Vitonis AF, Schock H, Husing A, Johnson T, Fichorova RN, et al. Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort. J Ovarian Res. 2017;10(1):20.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Chudecka-Glaz A, Cymbaluk-Ploska A, Strojna A, Menkiszak J. HE4 serum levels in patients with BRCA1 gene mutation undergoing prophylactic surgery as well as in other benign and malignant gynecological diseases. Dis Markers. 2017;2017:9792756.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, et al. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer. 2010;116(8):1918–25.

    Article  CAS  PubMed  Google Scholar 

  62. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra68.

    Article  PubMed  CAS  Google Scholar 

  63. Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H, et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS Med. 2016;13(12):e1002198.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Gloss BS, Samimi G. Epigenetic biomarkers in epithelial ovarian cancer. Cancer Lett. 2014;342(2):257–63.

    Article  CAS  PubMed  Google Scholar 

  65. Earp MA, Cunningham JM. DNA methylation changes in epithelial ovarian cancer histotypes. Genomics. 2015;106(6):311–21.

    Article  CAS  PubMed  Google Scholar 

  66. Giannopoulou L, Mastoraki S, Buderath P, Strati A, Pavlakis K, Kasimir-Bauer S, et al. ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer. Gynecol Oncol. 2018;150(2):355–60.

    Article  CAS  PubMed  Google Scholar 

  67. Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res. 2006;66(22):10795–804.

    Article  CAS  PubMed  Google Scholar 

  68. Buas MF, Gu H, Djukovic D, Zhu J, Drescher CW, Urban N, et al. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors. Gynecol Oncol. 2016;140(1):138–44.

    Article  CAS  PubMed  Google Scholar 

  69. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67(18):8699–707.

    Article  CAS  PubMed  Google Scholar 

  70. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110(1):13–21.

    Article  CAS  PubMed  Google Scholar 

  71. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009;112(1):55–9.

    Article  CAS  PubMed  Google Scholar 

  72. Zhang S, Lu Z, Unruh AK, Ivan C, Baggerly KA, Calin GA, et al. Clinically relevant microRNAs in ovarian cancer. Mol Cancer Res. 2015;13(3):393–401.

    Article  CAS  PubMed  Google Scholar 

  73. Wang H, Fu Z, Dai C, Cao J, Liu X, Xu J, et al. LncRNAs expression profiling in normal ovary, benign ovarian cyst and malignant epithelial ovarian cancer. Sci Rep. 2016;6:38983.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Zhong Y, Gao D, He S, Shuai C, Peng S. Dysregulated expression of long noncoding RNAs in ovarian cancer. Int J Gynecol Cancer. 2016;26(9):1564–70.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Worku T, Bhattarai D, Ayers D, Wang K, Wang C, Rehman ZU, et al. Long non-coding RNAs: the new horizon of gene regulation in ovarian cancer. Cell Physiol Biochem. 2017;44(3):948–66.

    Article  CAS  PubMed  Google Scholar 

  76. Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Jarle Christensen I, Gayther S, et al. Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish ‘MALOVA’ ovarian cancer study. Pathology. 2008;40(5):487–92.

    Article  CAS  PubMed  Google Scholar 

  77. Kawai M, Kano T, Kikkawa F, Morikawa Y, Oguchi H, Nakashima N, et al. Seven tumor markers in benign and malignant germ cell tumors of the ovary. Gynecol Oncol. 1992;45(3):248–53.

    Article  CAS  PubMed  Google Scholar 

  78. Chow SN, Yang JH, Lin YH, Chen YP, Lai JI, Chen RJ, et al. Malignant ovarian germ cell tumors. Int J Gynaecol Obstet. 1996;53(2):151–8.

    Article  CAS  PubMed  Google Scholar 

  79. Robertson DM, Pruysers E, Jobling T. Inhibin as a diagnostic marker for ovarian cancer. Cancer Lett. 2007;249(1):14–7.

    Article  CAS  PubMed  Google Scholar 

  80. Suzuki M, Ohwada M, Sato I, Nagatomo M. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies. Oncology. 1995;52(2):128–33.

    Article  CAS  PubMed  Google Scholar 

  81. Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995;71(2):354–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Lambeck AJ, Crijns AP, Leffers N, Sluiter WJ, ten Hoor KA, Braid M, et al. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res. 2007;13(8):2385–91.

    Article  CAS  PubMed  Google Scholar 

  83. Emami N, Diamandis EP. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin Chem. 2008;54(10):1600–7.

    Article  CAS  PubMed  Google Scholar 

  84. Hu ZD, Wei TT, Yang M, Ma N, Tang QQ, Qin BD, et al. Diagnostic value of osteopontin in ovarian cancer: a meta-analysis and systematic review. PLoS One. 2015;10(5):e0126444.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Huang CY, Cheng WF, Lee CN, Su YN, Chien SC, Tzeng YL, et al. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Res. 2006;26(6c):4721–8.

    CAS  PubMed  Google Scholar 

  86. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.

    Google Scholar 

  87. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7.

    Article  CAS  PubMed  Google Scholar 

  88. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.

    Article  CAS  PubMed  Google Scholar 

  89. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30(4):372–9.

    Article  CAS  PubMed  Google Scholar 

  90. Stover EH, Konstantinopoulos PA, Matulonis UA, Swisher EM. Biomarkers of response and resistance to DNA repair targeted therapies. Clin Cancer Res. 2016;22(23):5651–60.

    Article  CAS  PubMed  Google Scholar 

  91. Gadducci A, Ferdeghini M, Prontera C, Giordano P, Cristofani R, Bianchi R, et al. A comparison of pretreatment serum levels of four tumor markers in patients with endometrial and cervical carcinoma. Eur J Gynaecol Oncol. 1990;11(4):283–8.

    CAS  PubMed  Google Scholar 

  92. Kurihara T, Mizunuma H, Obara M, Andoh K, Ibuki Y, Nishimura T. Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma. Gynecol Oncol. 1998;69(3):192–6.

    Article  CAS  PubMed  Google Scholar 

  93. Chen YL, Huang CY, Chien TY, Huang SH, Wu CJ, Ho CM. Value of pre-operative serum CA125 level for prediction of prognosis in patients with endometrial cancer. Aust N Z J Obstet Gynaecol. 2011;51(5):397–402.

    Article  PubMed  Google Scholar 

  94. Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol. 2012;124(2):270–5.

    Article  CAS  PubMed  Google Scholar 

  95. Brennan DJ, Hackethal A, Metcalf AM, Coward J, Ferguson K, Oehler MK, et al. Serum HE4 as a prognostic marker in endometrial cancer—a population based study. Gynecol Oncol. 2014;132(1):159–65.

    Article  CAS  PubMed  Google Scholar 

  96. Vallone C, Rigon G, Gulia C, Baffa A, Votino R, Morosetti G, et al. Non-coding RNAs and endometrial cancer. Genes. 2018;9(4).

    Article  PubMed Central  CAS  Google Scholar 

  97. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.

    Article  PubMed  CAS  Google Scholar 

  98. Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1(9):1319–23.

    Article  PubMed  Google Scholar 

  99. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer. 1977;40(4):1621–8.

    Article  CAS  PubMed  Google Scholar 

  101. Gadducci A, Tana R, Fanucchi A, Genazzani AR. Biochemical prognostic factors and risk of relapses in patients with cervical cancer. Gynecol Oncol. 2007;107(1 Suppl 1):S23–6.

    Article  CAS  PubMed  Google Scholar 

  102. Charakorn C, Thadanipon K, Chaijindaratana S, Rattanasiri S, Numthavaj P, Thakkinstian A. The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: a systematic review and meta-analysis. Gynecol Oncol. 2018;150(1):190–200.

    Article  CAS  PubMed  Google Scholar 

  103. Bonfrer JM, Gaarenstroom KN, Kenter GG, Korse CM, Hart AA, Gallee MP, et al. Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer. Gynecol Oncol. 1994;55(3 Pt 1):371–5.

    Article  CAS  PubMed  Google Scholar 

  104. Gadducci A, Tana R, Cosio S, Genazzani AR. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol. 2008;66(1):10–20.

    Article  PubMed  Google Scholar 

  105. Lehtovirta P, Viinikka L, Ylikorkala O. Comparison between squamous cell carcinoma-associated antigen and CA-125 in patients with carcinoma of the cervix. Gynecol Oncol. 1990;37(2):276–8.

    Article  CAS  PubMed  Google Scholar 

  106. Borras G, Molina R, Xercavins J, Ballesta A, Iglesias J. Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix. Gynecol Oncol. 1995;57(2):205–11.

    Article  CAS  PubMed  Google Scholar 

  107. Battaglia F, Scambia G, Panici PB, Castelli M, Ferrandina G, Foti E, et al. Immunosuppressive acidic protein (IAP) and squamous cell carcinoma antigen (SCC) in patients with cervical cancer. Gynecol Oncol. 1994;53(2):176–82.

    Article  CAS  PubMed  Google Scholar 

  108. Mathur SP, Mathur RS, Gray EA, Lane D, Underwood PG, Kohler M, et al. Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A [corrected]. Gynecol Oncol. 2005;98(3):467–83.

    Article  CAS  PubMed  Google Scholar 

  109. Jia W, Wu Y, Zhang Q, Gao GE, Zhang C, Xiang Y. Expression profile of circulating microRNAs as a promising fingerprint for cervical cancer diagnosis and monitoring. Mol Clin Oncol. 2015;3(4):851–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Laengsri V, Kerdpin U, Plabplueng C, Treeratanapiboon L, Nuchnoi P. Cervical cancer markers: epigenetics and microRNAs. Lab Med. 2018;49(2):97–111.

    Article  PubMed  Google Scholar 

  111. Dong J, Su M, Chang W, Zhang K, Wu S, Xu T. Long non-coding RNAs on the stage of cervical cancer (Review). Oncol Rep. 2017;38(4):1923–31.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan

    Tatsuyuki Chiyoda, Ai Dozen, Keiko Saotome, Yoshiko Nanki & Daisuke Aoki

Authors
  1. Tatsuyuki Chiyoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ai Dozen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keiko Saotome
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshiko Nanki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daisuke Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tatsuyuki Chiyoda .

Editor information

Editors and Affiliations

  1. Gastroenterology Center (Surgery), Toho University Omori Medical Center, Tokyo, Japan

    Hideaki Shimada

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chiyoda, T., Dozen, A., Saotome, K., Nanki, Y., Aoki, D. (2019). Biomarkers of Gynecological Cancers. In: Shimada, H. (eds) Biomarkers in Cancer Therapy. Springer, Singapore. https://doi.org/10.1007/978-981-13-7295-7_13

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-7295-7_13

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-7294-0

  • Online ISBN: 978-981-13-7295-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation